| Literature DB >> 35114862 |
Joseph Tsai1, Balamurugan Vellayappan2, Vyshak Venur3, Tresa McGranahan3, Heidi Gray4, Renata R Urban4, Yolanda D Tseng1, Joshua Palmer5, Matthew Foote6, Nina A Mayr1, Stephanie E Combs7, Arjun Sahgal8, Eric L Chang9, Simon S Lo1.
Abstract
INTRODUCTION: Gestational trophoblastic diseases and neoplasias (GTDs and GTNs) comprise a spectrum of diseases arising from abnormally proliferating placental/trophoblastic tissue following an antecedent molar or non-molar pregnancy. These can spread to the brain hematogenously in about 10% of patients, mostly in high-risk disease. The optimal management of patients with brain metastases from GTN is unclear, with multiple systemic regimens under use and an uncertain role for radiotherapy. AREAS COVERED: Here, we review the epidemiology, workup, and treatment of GTN with central nervous system (CNS) involvement. Literature searches in PubMed and Google Scholar were conducted using combinations of keywords such as 'gestational trophoblastic disease,' 'gestational trophoblastic neoplasia,' 'choriocarcinoma,' and 'brain metastases.' EXPERT OPINION: Systemic therapy is the frontline treatment for GTN with brain metastases, and radiotherapy should only be considered in the context of a clinical trial or for resistant/recurrent disease. Surgery has a limited role in palliating symptoms or relieving intracranial pressure/bleeding. Given the highly specialized care these patients require, treatment at a high-volume referral center with multidisciplinary collaboration likely leads to better outcomes. Randomized trials should be conducted to determine the best systemic therapy option for GTN.Entities:
Keywords: EMA-CO; Gestational trophoblastic neoplasia; brain metastases; choriocarcinoma; whole-brain radiation therapy
Mesh:
Year: 2022 PMID: 35114862 DOI: 10.1080/14737140.2022.2038566
Source DB: PubMed Journal: Expert Rev Anticancer Ther ISSN: 1473-7140 Impact factor: 4.512